Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | PGR | P06401 | 3/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.70 |
| ▸ | AR | P10275 | 2/20 | 0.70 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.70 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.70 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.49 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4747192 | 0.89 | CYP3A4 (0.70) | CYP3A4ALDH1A1PGRCYP2C19AR | |
| SCHEMBL4746562 | 0.89 | CYP3A4 (0.70) | CYP3A4ALDH1A1PGRCYP2C19AR | |
| SCHEMBL10896735 | 0.86 | CYP3A4 (0.66) | CYP3A4ALDH1A1PGRCYP2C19AR | |
| Dydrogesterone SCHEMBL606817 | 0.82 | CYP3A4 (1.00) | CYP3A4ALDH1A1PGRCYP2C19AR | |
| Dydrogesterone SCHEMBL37703 | 0.82 | CYP3A4 (1.00) | CYP3A4ALDH1A1PGRCYP2C19AR | |
| Dydrogesterone SCHEMBL23360787 | 0.82 | CYP3A4 (1.00) | CYP3A4ALDH1A1PGRCYP2C19AR | |
| Dydrogesterone SCHEMBL18814051 | 0.82 | CYP3A4 (1.00) | CYP3A4ALDH1A1PGRCYP2C19AR | |
| Dydrogesterone SCHEMBL606816 | 0.82 | CYP3A4 (1.00) | CYP3A4ALDH1A1PGRCYP2C19AR | |
| Dydrogesterone SCHEMBL23383832 | 0.82 | CYP3A4 (1.00) | CYP3A4ALDH1A1PGRCYP2C19AR | |
| Dydrogesterone SCHEMBL13907084 | 0.82 | CYP3A4 (1.00) | CYP3A4ALDH1A1PGRCYP2C19AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10781183-B2 | Small molecule inducers of reactive oxygen species and inhibitors of mitochondrial activity | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-09-22 | — | — | US | disclosed |
| US-20190308942-A1 | SMALL MOLECULE INDUCERS OF REACTIVE OXYGEN SPECIES AND INHIBITORS OF MITOCHONDRIAL ACTIVITY | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-10-10 | — | — | US | disclosed |
| US-9192656-B2 | Methods and compositions for the treatment of cancer | QUINTESSENCE BIOSCIENCES, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9006407-B2 | Therapeutic ribonucleases | QUINTESSENCE BIOSCIENCES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20140128457-A1 | THERAPEUTIC RIBONUCLEASES | QUINTESSENCE BIOSCIENCES, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20130078229-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | QUINTESSENCE BIOSCIENCES, INC. | 2013-03-28 | — | — | US | disclosed |
| US-20120276077-A1 | THERAPEUTIC RIBONUCLEASES | QUINTESSENCE BIOSCIENCES, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-8298801-B2 | Human ribonuclease for use in prevention and treatment of cancer; antitumor agents | QUINTESSENCE BIOSCIENCES, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8029782-B2 | Therapeutic ribonucleases | QUINTESSENCE BIOSCIENCES, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20100080789-A1 | THERAPEUTIC RIBONUCLEASES | QUINTESSENCE BIOSCIENCES, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20080095755-A1 | Methods and compositions for the treatment of cancer | QUINTESSENCE BIOSCIENCES, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-5861387-A | TREATMENT AND PREVENTION OF BREAST AND ENDOMETRIAL CANCER, BONE LOSS, AND FOR TREATING ENDOMETRIOSIS | ENDORECHERCHE INC. (CA) | 1999-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308942-A1 | SMALL MOLECULE INDUCERS OF REACTIVE OXYGEN SPECIES AND INHIBITORS OF MITOCHONDRIAL ACTIVITY | SQOR, MAVS, TFAM | CYP3A4 840/4885ALDH1A1 1628/4885PGR 4307/4885 |
| US-10781183-B2 | Small molecule inducers of reactive oxygen species and inhibitors of mitochondrial activity | SQOR, MAVS, TFAM | CYP3A4 840/4885ALDH1A1 1628/4885PGR 4307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.